CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the ...

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

Purespring Therapeutics has secured approval for its UK clinical trial application (CTA) for a Phase I/II trial of its lead programme, PS-002.

Ocugen says it is on track to reshape the market for gene therapies against eye disorders over the next three years, by ...

The designation was based on the therapy’s novel mechanism and data showing its anti-tumour activity in B-cell malignancies.

KDPMA elects Jatish N Sheth as president for the term 2025 to 2027: Our Bureau, Bengaluru Wednesday, August 6, 2025, 15:45 Hrs [IST] Karnataka Drugs and Pharmaceuticals Manufactur ...

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Medicines Agency (EMA) has ...

US FDA clears Hemispherian’s IND application for first-in-class glioblastoma therapeutic, GLIX1: Oslo, Norway Wednesday, August 6, 2025, 15:00 Hrs [IST] Hemispherian AS, a pione ...

RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in ...